Mechanisms of Drug Interactions

  • Patrick F. D’Arcy
  • James C. McElnay
  • Peter G. Welling

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 122)

Table of contents

  1. Front Matter
    Pages I-XVI
  2. Introduction

    1. P. F. D’Arcy
      Pages 1-10
  3. Pharmacokinetic Drug Interactions

  4. Pharmacodynamic Drug Interactions

    1. Front Matter
      Pages 213-213
    2. M. Schorderet, J. D. Ferrero
      Pages 215-233
    3. J. P. Griffin, P. F. D’Arcy
      Pages 235-248
    4. J. C. McElnay, C. M. Hughes
      Pages 249-278
    5. J. C. McElnay, P. F. D’Arcy
      Pages 279-304
    6. S. Yosselson-Superstine
      Pages 305-326
    7. P. A. G. M. De Smet, P. F. D’Arcy
      Pages 327-352
  5. Back Matter
    Pages 353-363

About this book


Over the years a number of excellent books have classified and detailed drug­ drug interactions into their respective categories, e.g. interactions at plasma protein binding sites; those altering intestinal absorption or bioavailability; those involving hepatic metabolising enzymes; those involving competition or antagonism for receptor sites, and drug interactions modifying excretory mechanisms. Such books have presented extensive tables of interactions and their management. Although of considerable value to clinicians, such publica­ tions have not, however, been so expressive about the individual mechanisms that underlie these interactions. It is within this sphere of "mechanisms" that this present volume specialises. It deals with mechanisms of in vitro and in vivo, drug-drug, drug­ food and drug-herbals interactions and those that cause drugs to interfere with diagnostic laboratory tests. We believe that an explanation of the mechanisms of such interactions will enable practitioners to understand more fully the nature of the interactions and thus enable them to manage better their clinical outcome. If mechanisms of interactions are better understood, then it may be pos­ sible for the researcher to develop meaningful animal/biochemical/tissue cul­ ture or physicochemical models to which new molecules could be exposed during their development stages. The present position, which largely relies on patients experiencing adverse interactions before they can be established or documented, can hardly be regarded as satisfactory. This present volume is classified into two major parts; firstly, pharmacoki­ netic drug interactions and, secondly, pharmacodynamic drug interactions.


Filtration Wechselwirkung absorption amino acid chemotherapy drug enzyme enzymes kidney metabolism pharmacodynamics pharmacokinetics pharmacology physiology steroids

Editors and affiliations

  • Patrick F. D’Arcy
    • 1
  • James C. McElnay
    • 2
  • Peter G. Welling
    • 3
  1. 1.School of PharmacyThe Queen’s University of Belfast, Medical Biology CentreBelfastN. Ireland
  2. 2.School of PharmacyThe Queen’s University of Belfast, Medical Biology CentreBelfastN. Ireland
  3. 3.Pharmacokinetics and Drug MetabolismParke-Davis Pharmaceutical ResearchAnn ArborUSA

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1996
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-64658-4
  • Online ISBN 978-3-642-61015-8
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods